XASXCHM
Market cap5mUSD
Jan 02, Last price
0.01AUD
1D
0.00%
1Q
-57.14%
IPO
-98.06%
Name
Chimeric Therapeutics Ltd
Chart & Performance
P/E
—
P/S
1.48
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
7m
+65.52%
Net income
-13m
L-51.65%
CFO
-8m
L-53.74%
Earnings
Feb 26, 2025
Profile
Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies in oncology in Australia. The company develops CHM 0201 (core NK platform) that is in phase I clinical trial for treating solid tumors and hematological malignancies; and CHM 1101 (CLTX CAR T), which is in phase I clinical trial for treating patients with MMP2+ recurrent or progressive glioblastoma. It is also developing CHM 0301 for blood cancers; CHM 1301 (CLTX CAR NK) and CHM 2301 (CDH17 CAR NK) for solid tumors; CHM 1101 (CLTX CAR T) for melanoma, colorectal, and prostate; and CHM 2101 (CDH17 CAR T) for neuroendocrine, colorectal, pancreatic, and gastric. The company was incorporated in 2020 and is based in Carlton, Australia.
IPO date
Jan 18, 2021
Employees
Domiciled in
AU
Incorporated in
AU
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | |
| Income | |||||
Revenues | 7,458 65.52% | 4,506 72.16% | 2,617 98,808.62% | ||
Cost of revenue | 19,721 | 29,487 | 14,855 | ||
Unusual Expense (Income) | |||||
NOPBT | (12,263) | (24,981) | (12,238) | ||
NOPBT Margin | |||||
Operating Taxes | (3,750) | (4,413) | 164 | ||
Tax Rate | |||||
NOPAT | (8,513) | (20,569) | (12,402) | ||
Net income | (12,530) -51.65% | (25,917) 77.23% | (14,624) -3.24% | ||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 9,347 | 2,400 | 13,590 | ||
BB yield | -67.19% | -14.58% | -41.04% | ||
| Debt | |||||
Debt current | |||||
Long-term debt | |||||
Deferred revenue | |||||
Other long-term liabilities | 2,706 | 2,022 | 153 | ||
Net debt | (3,093) | (5,410) | (18,422) | ||
| Cash flow | |||||
Cash from operating activities | (7,548) | (16,316) | (13,153) | ||
CAPEX | 7,548 | (112) | (538) | ||
Cash from investing activities | (112) | (565) | |||
Cash from financing activities | 8,257 | 264 | 9,504 | ||
FCF | (6,974) | (15,217) | (12,404) | ||
| Balance | |||||
Cash | 3,053 | 5,370 | 18,382 | ||
Long term investments | 40 | 40 | 40 | ||
Excess cash | 2,720 | 5,184 | 18,291 | ||
Stockholders' equity | 2,470 | 5,661 | 26,585 | ||
Invested Capital | 2,706 | 2,499 | 7,568 | ||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 695,640 | 433,245 | 359,932 | ||
Price | 0.02 -47.37% | 0.04 -58.70% | 0.09 -68.28% | ||
Market cap | 13,913 -15.49% | 16,463 -50.28% | 33,114 -39.49% | ||
EV | 10,820 | 11,054 | 14,692 | ||
EBITDA | (11,257) | (24,016) | (11,288) | ||
EV/EBITDA | |||||
Interest | 332 | 774 | 640 | ||
Interest/NOPBT | |||||